Early results from randomized phase III trial of imatinib mesylate for gastrointestinal stromal tumors.
Patel
Shreyaskumar R
SR
D001549:Benzamides; D018592:Cross-Over Studies; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D010879:Piperazines / Q000008:administration & dosage*; D011379:Prognosis; D011743:Pyrimidines / Q000008:administration & dosage*; D017154:Stromal Cells / Q000473:pathology*; D015996:Survival Rate; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate